Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor
Interventions: DRUG: ex vivo-expanded HER2-specific T cells|DRUG: cyclophosphamide|BIOLOGICAL: denileukin diftitox|OTHER: flow cytometry|OTHER: immunoenzyme technique
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)